# Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

> **NCT04975152** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 36 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cemiplimab-Rwlc

## Key facts

- **NCT ID:** NCT04975152
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-22
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975152, "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04975152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*